Diet and Prostate Cancer; TTFields OK’d for NSCLC; Cancer Studies Retracted

A healthy diet in prostate cancer patients on active surveillance was associated with a reduced risk of progressing to a more advanced disease state. (JAMA Oncology)

Some doctors see a potential downside to FDA’s new requirement to notify women about breast density. (NBC News)

Jazz Pharmaceuticals announced that adding lurbinectedin (Zepzelca) to atezolizumab (Tecentriq) as first-line maintenance therapy for extensive-stage small cell lung cancer significantly improved progression-free and overall survival in a phase III trial.

The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 inhibitor or docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) who progressed on a platinum-based regimen, Novocure announced.

CDK4/6 inhibitor palbociclib (Ibrance) may be effective for patients with peritoneal mucinous carcinomatosis characterized by GNAS mutations, a small study indicated. (Journal of Clinical Oncology)

A helmet that applies pressure across the entire scalp could help prevent chemotherapy-induced hair loss. (CNN)

Radon exposure was linked with a higher risk of childhood leukemia. (Science of the Total Environment)

What can be done about the financial toxicity of a cancer diagnosis? (CNBC)

More and more breast cancer survivors are finding that their desire to opt out of breast reconstruction after mastectomy is being met by resistance from their doctors. (Cosmopolitan)

Sam Yoon, MD, Columbia University’s chief of surgical oncology, had five more research articles retracted over suspicious results. (New York Times)

Aura Biosciences said an ongoing phase I trial of belzupacap sarotalocan (AU-011) demonstrated activity in non-muscle invasive bladder cancer, including complete responses in four of five patients with low-grade disease who received the virus-like drug conjugate with light activation.

Please enable JavaScript to view the comments powered by Disqus.